{"id":8222,"date":"2020-06-09T09:45:20","date_gmt":"2020-06-09T14:45:20","guid":{"rendered":"https:\/\/saluddigital.com\/?p=8222"},"modified":"2025-11-05T12:42:57","modified_gmt":"2025-11-05T18:42:57","slug":"yale-mayo-clinic-utiliza-wearables-para-detectar-padecimientos-del-corazon","status":"publish","type":"post","link":"https:\/\/saluddigital.com\/en\/plataformas-digitales\/yale-mayo-clinic-utiliza-wearables-para-detectar-padecimientos-del-corazon\/","title":{"rendered":"Yale-Mayo Clinic uses wearables to detect heart conditions and improve drug development."},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Researchers from Yale-Mayo Clinic work with Biofourmis digital therapeutic specialists in the use of machine learning technology; the goal is to obtain information from biometric markers to improve medicines. <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The Yale-Mayo Clinic<\/strong> center of excellence and Biofourmis<\/strong>, a digital therapeutic company, have partnered to determine criteria for evaluating the effectiveness of patient-centered drug use that determine the development of drugs to treat heart failure.<\/p>

Based on these criteria, a 60-day test was initiated in August this year to capture patient information and analyze it on the BiovitalsHF<\/strong>, mobile health platform, developed by Biofourmis<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

For this, 2 biosensors are used that capture data, a medical grade Everion device, and an Apple Watch 4 series with ECG; which, through an app with machine learning technology, analyze dozens of physiological biomarkers, which can detect the heart's inability to maintain proper circulation, even weeks before a decompensation occurs.<\/p>

\u00a0<\/strong>The U.S. Food and Drug Administration (FDA)<\/strong> published a report on the development of drugs for the treatment of heart failure that states that \"end patient-centered data could be a basis for drug approval, and thus treat the disease as it is a problem affecting about 6.5 million patients in the United States.\"<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Rajput, Founder and CEO of Biofourmis<\/strong> commented, \"Since precision medicine is about getting the right dose of therapy for the right patient at the right time, being able to constantly capture biometric data 24 hours a day and 7 days a week, with patient-generated data will play a key role in the future of how the drug is being performed,\" adding, \"this approach will also help ensure that therapies are highly individualized.\"<\/p>

Biofourmis<\/strong> and Yale-Mayo Clinic<\/strong> researchers say their project will provide additional information that will enable the FDA to make sustained decisions.<\/p>

\u00a0<\/strong>All the implied benefits also include reducing research times and budgets that are reflected in reducing drug costs, as well as the amount of time patients need to travel to the clinic where researchers would collect the information.<\/p>

He also noted that recruiting patients for a clinical trial is one of the longest aspects of the drug approval process: \"by facilitating the process for patients by being monitored from the comfort of their own homes, patient recruitment is also much faster, which can also help shorten the duration of clinical trials during the drug approval process\" Rajput concluded.<\/p>

This is how technology available to all users is opening up great possibilities for researchers to obtain medical records and health-related activities in less time, costs and with greater scope, enabling better-sustained decision-making.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tBIBLIOGRAPHY<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

HEALTHCAREITNEWS<\/strong><\/p>

https:\/\/www.healthcareitnews.com\/news\/yale-mayo-clinic-use-biometric-data-wearables-reducing-drug-development-times<\/a><\/p>

FDA<\/strong><\/p>

https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Investigadores de Yale-Mayo Clinic trabajan con especialistas en terap\u00e9utica digital de Biofourmis en el uso de tecnolog\u00eda de aprendizaje autom\u00e1tico; el objetivo es obtener informaci\u00f3n de marcadores biom\u00e9tricos que permita mejorar medicamentos. El centro de excelencia Yale-Mayo Clinic y Biofourmis, empresa especialista en terap\u00e9utica digital, se han asociado para determinar criterios de evaluaci\u00f3n de la efectividad del uso de medicamentos, centrados en el paciente, que determinan el desarrollo de f\u00e1rmacos para tratar la insuficiencia cardiaca. Con base en estos criterios, en agosto del presente a\u00f1o se inici\u00f3 una prueba de 60 d\u00edas que capturar\u00e1 informaci\u00f3n de los pacientes y la analizar\u00e1 en la plataforma de salud m\u00f3vil BiovitalsHF, desarrollada por Biofourmis. Para esto, se utilizan 2 biosensores que capturan datos, un dispositivo Everion de grado m\u00e9dico, y un Apple Watch serie 4 con ECG; los cuales, por medio de una app con tecnolog\u00eda de aprendizaje autom\u00e1tico, analizan docenas de biomarcadores fisiol\u00f3gicos, con los cuales se puede detectar la incapa\u00adcidad del coraz\u00f3n para mantener una circulaci\u00f3n adecuada, incluso semanas antes de que ocurra una descompensaci\u00f3n. \u00a0La Administraci\u00f3n de Alimentos y Medicamentos de EE.UU. (FDA, por sus siglas en ingl\u00e9s), public\u00f3 un informe sobre el desarrollo de medicamentos para el tratamiento de insuficiencia cardiaca que indica que \u201clos datos finales centrados en el paciente podr\u00edan ser una base para la aprobaci\u00f3n de medicamentos, y as\u00ed tratar la enfermedad ya que es un problema que afecta alrededor de 6.5 millones de pacientes en Estados Unidos.\u201d Rajput, Fundador y CEO de Biofourmis coment\u00f3, “ya que la medicina de precisi\u00f3n se trata de obtener la dosis correcta de la terapia correcta para el paciente correcto en el momento correcto, ser capaz de capturar datos biom\u00e9tricos continuos las 24 horas del d\u00eda y los 7 d\u00edas de la semana, con datos generados por el paciente se jugar\u00e1n un papel clave en el futuro de c\u00f3mo el medicamento se realiza”, a\u00f1adiendo, “este enfoque tambi\u00e9n ayudar\u00e1 a garantizar que las terapias sean muy individualizadas”. Los investigadores de Biofourmis y Yale-Mayo Clinic aseguran que su proyecto ofrecer\u00e1 informaci\u00f3n complementaria que permitir\u00e1 a la FDA tomar decisiones sustentadas. \u00a0Entre todos los beneficios impl\u00edcitos, tambi\u00e9n se incluye la reducci\u00f3n de tiempos y presupuestos de investigaci\u00f3n que se ven reflejados en la reducci\u00f3n de costos de los f\u00e1rmacos, as\u00ed como en la cantidad de tiempo que los pacientes necesitan para viajar a la cl\u00ednica donde los investigadores recopilar\u00edan la informaci\u00f3n. Tambi\u00e9n se\u00f1al\u00f3 que el reclutamiento de pacientes para un ensayo cl\u00ednico es uno de los aspectos m\u00e1s largos del proceso de aprobaci\u00f3n de medicamentos: “al facilitar el proceso para los pacientes al ser monitoreados desde la comodidad de sus propios hogares, el reclutamiento de pacientes tambi\u00e9n es mucho m\u00e1s r\u00e1pido, lo que tambi\u00e9n puede ayudar a acortar la duraci\u00f3n de los ensayos cl\u00ednicos durante el proceso de aprobaci\u00f3n de medicamentos”, concluy\u00f3 Rajput. Es as\u00ed como la tecnolog\u00eda al alcance de todos los usuarios est\u00e1 abriendo grandes posibilidades para que los investigadores puedan obtener registros m\u00e9dicos y de actividades relacionadas con la salud en menor tiempo, costos y con mayor alcance, permitiendo la toma de decisiones mejor sustentadas. BIBLIOGRAF\u00cdA HEALTHCAREITNEWS https:\/\/www.healthcareitnews.com\/news\/yale-mayo-clinic-use-biometric-data-wearables-reducing-drug-development-times FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry<\/p>","protected":false},"author":1,"featured_media":8223,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[156,155,153],"tags":[145],"class_list":["post-8222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-big-data","category-el-mundo-en-la-nube","category-plataformas-digitales","tag-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/8222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/comments?post=8222"}],"version-history":[{"count":0,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/8222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media\/8223"}],"wp:attachment":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media?parent=8222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/categories?post=8222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/tags?post=8222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}